Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #794; 601; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Prior studies comparing letermovir (LET) and high-dose valacyclovir (VAL) for CMV prophylaxis primarily included high-risk patients, such as those with haploidentical or mismatched unrelated donors receiving post-transplant cyclophosphamide (PTCy)...Tacrolimus/methotrexate was the most frequent GVHD prophylaxis (65%)... No significant difference was observed in CMV infection rates between LET and VAL prophylaxis, although the incidence trended lower with LET. LET was associated with a higher rate of HHV-6 reactivation. Rates of acute and chronic GVHD, as well as 6-month survival, did not differ between groups."
Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation
|
|
Sanja Zepcan; Moujtaba Kasmani; Rachel Pionke; Emily Rux; Stephanie Tsai; Imran Puthawala; Patrick Hagen; Jorgena Kosti-Schwartz
|